https://auntresodamid.com/iJugHxINePLH1VY/96561

Biotechnology

Walgreens stock plunges as drugstore chain slashes profit guidance in ‘challenging’ consumer environment

Walgreens stock plunges as drugstore chain slashes profit guidance in ‘challenging’ consumer environment

In an aerial view, a customer enters a Walgreens store on January 04, 2024 in San Pablo, California.  Justin Sullivan | Getty Images Shares of Walgreens plunged more than 14% on Thursday after the company reported fiscal third-quarter earnings that fell short of expectations and slashed its full-year adjusted profit outlook, citing a “challenging” environment […]

Walgreens stock plunges as drugstore chain slashes profit guidance in ‘challenging’ consumer environment Read More »

Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers

Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers

US President Joe Biden speaks during an event at the National Institutes of Health (NIH) in Bethesda, Maryland, US, on Thursday, Dec. 14 2023.  Chris Kleponis | Bloomberg | Getty Images The Biden administration on Wednesday said it will impose inflation penalties on 64 prescription drugs for the third quarter of this year, lowering costs

Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers Read More »

Novo Nordisk to build .1 billion North Carolina facility to boost output of Wegovy, Ozempic

Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, Ozempic

Novo Nordisk’s new manufacturing facility in Clayton, North Carolina. Courtesy: Novo Nordisk Novo Nordisk on Monday said it will spend $4.1 billion to build a new manufacturing plant in Clayton, North Carolina, in a bid to boost the supply of its blockbuster weight loss drug Wegovy, diabetes treatment Ozempic and other injectable therapies.  Demand for

Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, Ozempic Read More »

Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year

Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year

Eli Lilly on Friday said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related breathing disorder and expects regulators to make a decision as early as the end of the year. If cleared by the Food and Drug Administration, the company plans to launch Zepbound for so-called obstructive

Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year Read More »

Don’t miss latest news!

Select list(s):

We don’t spam! Read our [link]privacy policy[/link] for more info.

Scroll to Top